Advertisement
GNOM vs MRNA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GNOM is a Hold and MRNA is a Hold.
Momentum Indicator for GNOM turns negative, indicating new downward trend
GNOM saw its Momentum Indicator move below the 0 level on October 06, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 101 similar instances where the indicator turned negative. In 96 of the 101 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for GNOM moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 25 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Moving Average Convergence Divergence Histogram (MACD) for GNOM turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 52 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
GNOM moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNOM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
GNOM broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where GNOM advanced for three days, in 224 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 181 of 194 cases where GNOM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
MRNA's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Indicator for MRNA moved out of overbought territory on October 16, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 instances where the indicator moved out of the overbought zone. In 25 of the 27 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
MRNA broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 17, 2026. You may want to consider a long position or call options on MRNA as a result. In 71 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for MRNA just turned positive on October 12, 2026. Looking at past instances where MRNA's MACD turned positive, the stock continued to rise in 35 of 40 cases over the following month. The odds of a continued upward trend are 88%.
Following a +9.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in 212 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 99 of 130 cases where MRNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 1 (best 1 - 100 worst), indicating outstanding price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.655) is normal, around the industry mean (26.823). P/E Ratio (26.455) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (25.907) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
MRNA | ||
|---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 97 | |
PRICE GROWTH RATING 1..100 | 1 | |
P/E GROWTH RATING 1..100 | 3 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| GNOM | MRNA | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 89% | 3 days ago 90% |
| Stochastic ODDS (%) | 3 days ago 90% | 3 days ago 78% |
| Momentum ODDS (%) | 3 days ago 90% | 3 days ago 82% |
| MACD ODDS (%) | 3 days ago 90% | 3 days ago 88% |
| TrendWeek ODDS (%) | 3 days ago 90% | 3 days ago 85% |
| TrendMonth ODDS (%) | 3 days ago 90% | 3 days ago 80% |
| Advances ODDS (%) | 4 days ago 86% | 4 days ago 78% |
| Declines ODDS (%) | 6 days ago 90% | 18 days ago 87% |
| BollingerBands ODDS (%) | 3 days ago 90% | 3 days ago 79% |
| Aroon ODDS (%) | 3 days ago 90% | 3 days ago 76% |
Advertisement
GNOM and
Correlation & Price change
A.I.dvisor indicates that over the last year, GNOM has been closely correlated with CRSP. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if GNOM jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To GNOM | 1D Price Change % | ||
|---|---|---|---|---|
| GNOM | 100% | -4.03% | ||
| CRSP - GNOM | 71% Closely correlated | -4.41% | ||
| TWST - GNOM | 71% Closely correlated | -8.13% | ||
| MRNA - GNOM | 69% Closely correlated | -7.82% | ||
| NTRA - GNOM | 63% Loosely correlated | -2.80% | ||
| TXG - GNOM | 62% Loosely correlated | -3.49% | ||
More | ||||